These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37840155)

  • 1. Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.
    Fediuk DJ; Gorman DN; Stoddard SA; Zhang Y; Ogden AG; Winton JA; Saxena AR
    J Clin Pharmacol; 2024 Apr; 64(4):449-460. PubMed ID: 37840155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
    Saxena AR; Frias JP; Gorman DN; Lopez RN; Andrawis N; Tsamandouras N; Birnbaum MJ
    Diabetes Obes Metab; 2023 Oct; 25(10):2805-2814. PubMed ID: 37311722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
    Ono R; Furihata K; Ichikawa Y; Nakazuru Y; Bergman A; Gorman DN; Saxena AR
    Diabetes Obes Metab; 2023 Mar; 25(3):805-814. PubMed ID: 36433713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.
    Saxena AR; Gorman DN; Esquejo RM; Bergman A; Chidsey K; Buckeridge C; Griffith DA; Kim AM
    Nat Med; 2021 Jun; 27(6):1079-1087. PubMed ID: 34127852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
    J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Saxena AR; Frias JP; Brown LS; Gorman DN; Vasas S; Tsamandouras N; Birnbaum MJ
    JAMA Netw Open; 2023 May; 6(5):e2314493. PubMed ID: 37213102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Martin J; Loghin C
    Clin Pharmacokinet; 2021 Aug; 60(8):1049-1059. PubMed ID: 33778934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
    Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Bello A; Murthy B
    Clin Pharmacokinet; 2022 Oct; 61(10):1405-1416. PubMed ID: 35906349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
    Hanefeld M; Arteaga JM; Leiter LA; Marchesini G; Nikonova E; Shestakova M; Stager W; Gómez-Huelgas R
    Diabetes Obes Metab; 2017 Nov; 19(11):1594-1601. PubMed ID: 28449324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
    Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.
    Klein G; Petrone M; Yang Y; Hoang T; Hazlett S; Hansen L; Flor A
    Clin Pharmacokinet; 2023 Jun; 62(6):881-890. PubMed ID: 37140727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
    Mosenzon O; Miller EM; Warren ML
    Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.
    Wang X; Yun Y; Chen L; Guo S; Niu B; Fang J; Yuan Q; Shen J; Xie X; Wang K
    Bioorg Med Chem; 2024 Jun; 107():117761. PubMed ID: 38795571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
    Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
    Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
    Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function.
    Shi D; Chen L; Li G; Wu N; Zhang F; Wang X; Mu N; Chen X; Yang X; Lu J; Lu Y; Wang M; Zhang D
    Clin Pharmacokinet; 2024 Feb; 63(2):227-239. PubMed ID: 38184489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.